Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | OXTR | P30559 | 12/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 8/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3565103 | 0.89 | POLB (0.45) | POLBOXTRAVPR1ATP53GAA | |
| SCHEMBL3565107 | 0.81 | STK17B (0.38) | POLBOXTRAVPR1A | |
| SCHEMBL5089101 | 0.79 | STK17B (0.36) | POLBOXTRAVPR1AGAA | |
| SCHEMBL3567825 | 0.79 | MET (0.42) | OXTRAVPR1A | |
| SCHEMBL3567819 | 0.79 | MET (0.42) | OXTRAVPR1A | |
| SCHEMBL1337005 | 0.75 | NPC1 (0.59) | POLBOXTRAVPR1AGAA | |
| Hydrochloric Acid SCHEMBL1336911 | 0.74 | NPC1 (0.58) | POLBOXTRAVPR1AGAA | |
| SCHEMBL15225861 | 0.73 | HTT (0.41) | POLBTP53MAPT | |
| SCHEMBL3575864 | 0.73 | MET (0.68) | — | |
| SCHEMBL13166773 | 0.72 | MET (0.41) | OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | POLB 1354/4885OXTR 943/4885AVPR1A 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.